ML STRATEGIES, LLC for ASTELLAS PHARMA US, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 16, 2008 | $60,000 | Replaced |
| 3rd Quarter - Amendment | Jan 6, 2010 | $60,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
S. 2313 and H.R. 3697, The Strategies to Address Antimicrobial Resistyance (STAAR Act); S. 2278, The Community and Healthcare Associated Infections (CHAI) Reduction Act; H. Res. 988 and S. Res. 454 MRSA Awareness Month. H. R. 6432, Animal Drug User Fee Amendments of 2008; S. 3560, Q1 Program Suplemental Funding Act of 2008, provisions regarding antibiotics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID LEITER | — |
| JEREMY RABINOVITZ | Chief of Staff to Congresswoman Lois Capps |
Medicare/Medicaid MMM
Issues related to the implementation of Section 501 (c) of the 2005 Deficit Reduction Act; S. 1951 and H.R. 3700, The Fair Medicaid Drug Payment Act, Section 2 (b) Prior Authorization Programs; S. 1887. and H.R. 3061 Amending Title XVIII of the Social Security Act to ensure access to critical medications under Medicare Part D; H.R. 6331, The Medicare Improvements for Patients and Providers Act; provisions relating to six classes of clinical concern under Medicare Part D.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID LEITER | — |
| JEREMY RABINOVITZ | Chief of Staff - Congresswoman Lois Capps |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.